$250 | Single User
$500 | Site License
$750 | Global License

Aerie Pharmaceuticals Inc (AERI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 09-11-2018]

Published by Global Data: 09 Nov 2018 | 226904 | In Stock

Introduction

Summary

Aerie Pharmaceuticals Inc (Aerie) is a pharmaceutical company that discovers, develops and commercializes therapies for the treatment of patients with glaucoma and other diseases of the eye. The company’s product candidates comprise rhopressa, a once-daily eye drop which is used for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; and roclatan, a fixed-dose combination of rhopressa and latanoprost. Aerie works in partnership with other pharma companies and universities for drug discovery technologies. The company has presence in the US and Ireland. Aerie is headquartered in Irvine, California, the US.

Aerie Pharmaceuticals Inc (AERI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.

- Business Description - A brief description of the company's operations.

- Key Employees - A list of the key executives of the company.

- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors - A list of the key competitors of the company.

- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents
for Aerie Pharmaceuticals Inc (AERI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 09-11-2018]

  • Table of Contents

    Table of Contents 3

    List of Tables 5

    List of Figures 5

    Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

    Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

    Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

    Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

    Aerie Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

    Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

    Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

    Asset Purchase 12

    Aerie Pharma Acquires Rights of PRINT Technology and Other Assets from Envisia Therapeutics 12

    Venture Financing 13

    Aerie Pharma Raises Additional USD12 Million in Venture Financing 13

    Aerie Pharma Raises US Million In Venture Financing 14

    Partnerships 15

    ViSci Enters Into Option Agreement with Novaer to License Eye-D Technology 15

    Aerie Pharma Enters into R&D Agreement with Royal DSM 16

    Licensing Agreements 17

    Aerie Pharma Expands Licensing Agreement with DSM Biomedical 17

    Aerie Pharma Enters into Licensing Agreement with Ramot at Tel Aviv University 18

    Aerie Pharma Enters into Licensing Agreement with GrayBug 19

    Equity Offering 20

    Aerie Pharma Raises USD74.3 Million in Public Offering of Shares 20

    Aerie Pharma Raises USD75 Million in Public Offering of Shares 22

    Aerie Pharma Raises USD75 Million in Public Offering of Shares 24

    Aerie Pharma Plans Public Offering of Shares for up to USD50 Million 26

    Aerie Pharma Completes IPO For US.3 Million 27

    Debt Offering 29

    Aerie Pharma Raises USD125 Million in Private Placement of 1.75% Notes Due 2021 29

    Aerie Pharmaceuticals Inc - Key Competitors 31

    Aerie Pharmaceuticals Inc - Key Employees 32

    Aerie Pharmaceuticals Inc - Locations And Subsidiaries 34

    Head Office 34

    Other Locations & Subsidiaries 34

    Recent Developments 35

    Strategy And Business Planning 35

    Oct 23, 2018: Aerie Pharmaceuticals establishes GMP PRINT production facility in an expanded global headquarters 35

    Financial Announcements 36

    Nov 06, 2018: Aerie Pharmaceuticals reports third quarter 2018 financial results and provides business update 36

    Aug 08, 2018: Aerie Pharmaceuticals reports second quarter 2018 financial results and provides business update 38

    May 08, 2018: Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update 39

    Feb 28, 2018: Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update and 2018 Guidance 40

    Nov 08, 2017: Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update 42

    Aug 01, 2017: Aerie Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 43

    May 02, 2017: Aerie Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update 44

    Mar 07, 2017: Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 45

    Corporate Communications 46

    Sep 12, 2018: Aerie Pharmaceuticals names David W. Gryska as Board Director 46

    Dec 04, 2017: Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region 47

    Aug 28, 2017: Aerie Pharmaceuticals Announces Appointment of Deanne Melloy as Vice President of Marketing and Norbert Lowe as Regional Sales Director 48

    Apr 24, 2017: Aerie Pharmaceuticals Announces Appointment of Raymond S. Wysmierski as Director of Compliance 49

    Apr 10, 2017: Aerie Pharmaceuticals Announces Expansion of Commercialization Team 50

    Product News 51

    12/18/2017: Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension 51

    08/15/2018: Aerie Pharmaceuticals Reports Topline Result from Rhopressa Mechanism of Action Study 52

    05/03/2017: Envisia Therapeutics Announces New Data On ENV1105 At ASCRS 2017 Annual Meeting 53

    04/30/2018: Aerie Pharmaceuticals Announces U.S. Launch of Rhopressa (netarsudil ophthalmic solution) 0.02% 54

    Feb 21, 2018: New glaucoma drugs yield large, lasting reductions in intraocular pressure 55

    Product Approvals 56

    Oct 13, 2017: Aerie Pharmaceuticals Announces FDA Advisory Committee Vote in Favor of Rhopressa (netarsudil ophthalmic solution) 0.02% 56

    Sep 20, 2017: Aerie Pharmaceuticals Announces FDA Advisory Committee Meeting for Rhopressa (netarsudil ophthalmic solution) 0.02% 57

    Aug 08, 2017: Aerie Pharmaceuticals Comments on Notification from Contract Manufacturer 58

    May 15, 2017: Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa (netarsudil ophthalmic solution) 0.02% 59

    Mar 01, 2017: Aerie Pharmaceuticals Announces Resubmission of NDA for Rhopressa (netarsudil ophthalmic solution) 0.02% 60

    Clinical Trials 61

    Oct 09, 2018: Aerie Pharmaceuticals Announces Drug Application for Regulatory Approval Accepted for Review in Europe 61

    Nov 16, 2017: Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan 62

    Apr 12, 2017: Aerie Pharmaceuticals Reports Positive Rocket 4 Six-Month Topline Safety and Efficacy Results for RhopressaTM (netarsudil ophthalmic solution) 0.02% 63

    Appendix 66

    Methodology 66

    About GlobalData 66

    Contact Us 66

    Disclaimer 66

List Of Tables
in Aerie Pharmaceuticals Inc (AERI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 09-11-2018]

List of Tables

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aerie Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Aerie Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Aerie Pharma Acquires Rights of PRINT Technology and Other Assets from Envisia Therapeutics 12

Aerie Pharma Raises Additional USD12 Million in Venture Financing 13

Aerie Pharma Raises US Million In Venture Financing 14

ViSci Enters Into Option Agreement with Novaer to License Eye-D Technology 15

Aerie Pharma Enters into R&D Agreement with Royal DSM 16

Aerie Pharma Expands Licensing Agreement with DSM Biomedical 17

Aerie Pharma Enters into Licensing Agreement with Ramot at Tel Aviv University 18

Aerie Pharma Enters into Licensing Agreement with GrayBug 19

Aerie Pharma Raises USD74.3 Million in Public Offering of Shares 20

Aerie Pharma Raises USD75 Million in Public Offering of Shares 22

Aerie Pharma Raises USD75 Million in Public Offering of Shares 24

Aerie Pharma Plans Public Offering of Shares for up to USD50 Million 26

Aerie Pharma Completes IPO For US.3 Million 27

Aerie Pharma Raises USD125 Million in Private Placement of 1.75% Notes Due 2021 29

Aerie Pharmaceuticals Inc, Key Competitors 31

Aerie Pharmaceuticals Inc, Key Employees 32

Aerie Pharmaceuticals Inc, Other Locations 34

Aerie Pharmaceuticals Inc, Subsidiaries 34

List Of Figures, Charts and Diagrams
in Aerie Pharmaceuticals Inc (AERI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 09-11-2018]

List of Figures

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aerie Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Additional Details

Publisher

Global Data

Publisher Information

Reference

226904 | GDPH140531D

Number of Pages

66

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Aerie Pharmaceuticals Inc (AERI) - Financial and Strategic SWOT Analysis Review
SummaryAerie Pharmaceuticals Inc (Aerie) is a pharmaceutical company that discovers, develops and co...
13 Nov 2017 by Global Data USD $300 More Info
Aerie Pharmaceuticals Inc (AERI) - Financial and Strategic SWOT Analysis Review
SummaryAerie Pharmaceuticals Inc (Aerie) is a pharmaceutical company that discovers, develops and co...
07 Aug 2017 by Global Data USD $300 More Info
Aerie Pharmaceuticals Inc (AERI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.
SummaryAerie Pharmaceuticals Inc (Aerie) is a pharmaceutical company that discovers, develops and co...
20 Jul 2017 by Global Data USD $250 More Info
Aerie Pharmaceuticals Inc (AERI) - Financial and Strategic SWOT Analysis Review
SummaryAerie Pharmaceuticals Inc (Aerie) is a pharmaceutical company that discovers, develops and co...
15 May 2017 by Global Data USD $300 More Info
Aerie Pharmaceuticals Inc (AERI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryAerie Pharmaceuticals Inc (Aerie) is a pharmaceutical company that discovers, develops and co...
25 Jan 2017 by Global Data USD $250 More Info
Aerie Pharmaceuticals Inc (AERI) - Financial and Strategic SWOT Analysis Review
SummaryAerie Pharmaceuticals Inc (Aerie) is a pharmaceutical company that discovers, develops and co...
13 Jan 2017 by Global Data USD $300 More Info
Aerie Pharmaceuticals Inc (AERI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryAerie Pharmaceuticals Inc (Aerie) is a pharmaceutical company that discovers, develops and co...
21 Nov 2016 by Global Data USD $250 More Info
Aerie Pharmaceuticals, Inc. (AERI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryAerie Pharmaceuticals, Inc. (Aerie) is a pharmaceutical company that discovers, develops and ...
29 Jul 2016 by Global Data USD $250 More Info
Aerie Pharmaceuticals, Inc. (AERI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryAerie Pharmaceuticals, Inc. (Aerie) is a pharmaceutical company that discovers, develops and ...
05 May 2016 by Global Data USD $250 More Info
Aerie Pharmaceuticals, Inc. (AERI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryAerie Pharmaceuticals, Inc. (Aerie) is a pharmaceutical company that discovers, develops and ...
08 Mar 2016 by Global Data USD $250 More Info

This report is published by Global Data

Download Free Report Summary PDF

Aerie Pharmaceuticals Inc (AERI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 09-11-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data